Banco Santander S.A. trimmed its holdings in shares of CVS Health Co. (NYSE:CVS - Free Report) by 23.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 67,467 shares of the pharmacy operator's stock after selling 21,171 shares during the period. Banco Santander S.A.'s holdings in CVS Health were worth $4,242,000 at the end of the most recent reporting period.
Several other large investors also recently made changes to their positions in the business. Pzena Investment Management LLC raised its position in CVS Health by 132.9% in the second quarter. Pzena Investment Management LLC now owns 12,936,388 shares of the pharmacy operator's stock valued at $764,023,000 after purchasing an additional 7,382,931 shares during the period. Pathway Financial Advisers LLC raised its position in CVS Health by 5,864.2% in the third quarter. Pathway Financial Advisers LLC now owns 1,730,343 shares of the pharmacy operator's stock valued at $108,804,000 after purchasing an additional 1,701,331 shares during the period. State of Michigan Retirement System raised its position in CVS Health by 402.5% in the second quarter. State of Michigan Retirement System now owns 2,005,677 shares of the pharmacy operator's stock valued at $118,455,000 after purchasing an additional 1,606,500 shares during the period. Swedbank AB purchased a new position in CVS Health in the first quarter valued at about $110,816,000. Finally, AQR Capital Management LLC raised its position in CVS Health by 33.5% in the second quarter. AQR Capital Management LLC now owns 5,289,788 shares of the pharmacy operator's stock valued at $310,722,000 after purchasing an additional 1,327,855 shares during the period. Institutional investors and hedge funds own 80.66% of the company's stock.
CVS Health Stock Performance
CVS stock traded up $0.91 during midday trading on Friday, reaching $58.01. The company had a trading volume of 10,428,506 shares, compared to its average volume of 11,356,283. The company has a quick ratio of 0.59, a current ratio of 0.80 and a debt-to-equity ratio of 0.80. The stock has a 50 day moving average price of $59.21 and a 200 day moving average price of $58.59. CVS Health Co. has a fifty-two week low of $52.71 and a fifty-two week high of $83.25. The firm has a market capitalization of $73.00 billion, a PE ratio of 14.72, a P/E/G ratio of 0.94 and a beta of 0.55.
CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.01. The business had revenue of $95.43 billion during the quarter, compared to the consensus estimate of $92.72 billion. CVS Health had a return on equity of 10.72% and a net margin of 1.36%. The business's revenue was up 6.3% on a year-over-year basis. During the same period in the previous year, the firm posted $2.21 earnings per share. Analysts anticipate that CVS Health Co. will post 5.43 earnings per share for the current year.
CVS Health Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Stockholders of record on Monday, October 21st were given a dividend of $0.665 per share. The ex-dividend date was Monday, October 21st. This represents a $2.66 annualized dividend and a dividend yield of 4.59%. CVS Health's dividend payout ratio is presently 67.51%.
Wall Street Analyst Weigh In
Several research analysts have commented on CVS shares. Wells Fargo & Company raised CVS Health from an "equal weight" rating to an "overweight" rating and raised their price objective for the company from $60.00 to $66.00 in a research report on Monday. Evercore ISI raised their price objective on CVS Health from $62.00 to $75.00 and gave the company an "outperform" rating in a research report on Tuesday, October 8th. UBS Group lifted their target price on CVS Health from $60.00 to $62.00 and gave the stock a "neutral" rating in a research report on Thursday, November 7th. Barclays dropped their target price on CVS Health from $75.00 to $71.00 and set an "overweight" rating on the stock in a research report on Thursday, November 7th. Finally, Mizuho dropped their target price on CVS Health from $73.00 to $66.00 and set an "outperform" rating on the stock in a research report on Thursday, October 24th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and thirteen have given a buy rating to the company's stock. Based on data from MarketBeat, CVS Health presently has a consensus rating of "Moderate Buy" and a consensus price target of $72.28.
Check Out Our Latest Research Report on CVS Health
CVS Health Company Profile
(
Free Report)
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
Featured Stories
Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
